{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:31:31Z","timestamp":1787020291567,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:00:00Z","timestamp":1603843200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:00:00Z","timestamp":1603843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"This study was supported in part by Research Fund of Aier Eye Hospital Group","award":["AFM1078D1"],"award-info":[{"award-number":["AFM1078D1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>At present, patients with ocular myasthenia gravis (OMG) are typically treated with systemic drugs. We investigated the use of dexamethasone injected in the peribulbar region or extraocular muscle to treat patients with OMG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with OMG were given dexamethasone via peribulbar injection or direct injection into the main paralyzed extraocular muscles, once a week, for 4\u20136\u2009weeks. The severity of diplopia, blepharoptosis, eye position, and eye movement were evaluated before and after treatment. The duration of follow-up time was \u22656\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 14 patients with OMG who received this treatment, mean age was 38.7\u2009\u00b1\u200929.7\u2009years. After treatment, symptoms were relieved in 12 patients (85.7%), 1 patient (7.1%) had partial response to treatment, and 1 patient (7.1%) had no response. Two patients (14.2%) experienced symptom recurrence during the follow-up period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dexamethasone peribulbar or extraocular muscle injection is effective in the treatment of patients with OMG and may replace systemic drug therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Chinese Clinical Trial Registry,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\/showproj.aspx?proj=62056\">ChiCTR2000038863<\/jats:ext-link>\n                      , October 7, 2020.Retrospectively registered.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12886-020-01697-2","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T09:03:06Z","timestamp":1603875786000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Local use of dexamethasone in the treatment of ocular myasthenia gravis"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5715-7012","authenticated-orcid":false,"given":"Minghua","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjia","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijiao","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxing","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,28]]},"reference":[{"issue":"3","key":"1697_CR1","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1159\/000279334","volume":"34","author":"A McGrogan","year":"2010","unstructured":"McGrogan A, Sneddon S, de Vries CS. The incidence of myasthenia gravis: a systematic literature review. Neuroepidemiology. 2010;34(3):171\u201383.","journal-title":"Neuroepidemiology."},{"issue":"12","key":"1697_CR2","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s00415-010-5651-z","volume":"257","author":"I Casetta","year":"2010","unstructured":"Casetta I, Groppo E, De Gennaro R, Cesnik E, Piccolo L, Volpato S, Granieri E. Myasthenia gravis: a changing pattern of incidence. J Neurol. 2010;257(12):2015\u20139.","journal-title":"J Neurol."},{"issue":"1","key":"1697_CR3","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/mus.24350","volume":"51","author":"HT Benamer","year":"2015","unstructured":"Benamer HT, Bredan A. The epidemiology of myasthenia gravis in Arab countries: a systematic review. Muscle Nerve. 2015;51(1):144\u20135.","journal-title":"Muscle Nerve."},{"issue":"10","key":"1697_CR4","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14(10):1023\u201336.","journal-title":"Lancet Neurol."},{"issue":"6","key":"1697_CR5","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s10072-012-1157-z","volume":"34","author":"X Huang","year":"2013","unstructured":"Huang X, Liu WB, Men LN, Feng HY, Li Y, Luo CM, Qiu L. Clinical features of myasthenia gravis in southern China: a retrospective review of 2,154 cases over 22 years. Neurol Sci. 2013;34(6):911\u20137.","journal-title":"Neurol Sci."},{"key":"1697_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.pediatrneurol.2018.06.007","volume":"87","author":"K Vanikieti","year":"2018","unstructured":"Vanikieti K, Lowwongngam K, Padungkiatsagul T, Visudtibhan A, Poonyathalang A. Juvenile ocular myasthenia gravis: presentation and outcome of a large cohort. Pediatr Neurol. 2018;87:36\u201341.","journal-title":"Pediatr Neurol."},{"issue":"1","key":"1697_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/WCO.0b013e3282f4098e","volume":"21","author":"U Luchanok","year":"2008","unstructured":"Luchanok U, Kaminski HJ. Ocular myasthenia: diagnostic and treatment recommendations and the evidence base. Curr Opin Neurol. 2008;21(1):8\u201315.","journal-title":"Curr Opin Neurol."},{"issue":"6","key":"1697_CR8","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/ICU.0000000000000526","volume":"29","author":"E Fortin","year":"2018","unstructured":"Fortin E, Cestari DM, Weinberg DH. Ocular myasthenia gravis: an update on diagnosis and treatment. Curr Opin Ophthalmol. 2018;29(6):477\u201384.","journal-title":"Curr Opin Ophthalmol."},{"key":"1697_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2147\/NDT.S8915","volume":"7","author":"R Mantegazza","year":"2011","unstructured":"Mantegazza R, Bonanno S, Camera G, Antozzi C. Current and emerging therapies for the treatment of myasthenia gravis. Neuropsychiatr Dis Treat. 2011;7:151\u201360.","journal-title":"Neuropsychiatr Dis Treat."},{"issue":"3","key":"1697_CR10","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1067\/mtc.2001.116191","volume":"122","author":"PF Roberts","year":"2001","unstructured":"Roberts PF, Venuta F, Rendina E, De Giacomo T, Coloni GF, Follette DM, Richman DP, Benfield JR. Thymectomy in the treatment of ocular myasthenia gravis. J Thorac Cardiovasc Surg. 2001;122(3):562\u20138.","journal-title":"J Thorac Cardiovasc Surg."},{"issue":"1","key":"1697_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1471-2415-13-39","volume":"13","author":"S Tempest-Roe","year":"2013","unstructured":"Tempest-Roe S, Joshi L, Dick AD, Taylor SR. Local therapies for inflammatory eye disease in translation: past, present and future. BMC Ophthalmol. 2013;13(1):39.","journal-title":"BMC Ophthalmol."},{"issue":"3","key":"1697_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s12016-014-8436-9","volume":"49","author":"I Foeldvari","year":"2015","unstructured":"Foeldvari I. Ocular involvement in juvenile idiopathic arthritis: classification and treatment. Clin Rev Allergy Immunol. 2015;49(3):271\u20137.","journal-title":"Clin Rev Allergy Immunol."},{"issue":"5","key":"1697_CR13","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00296-011-2126-1","volume":"32","author":"A Heiligenhaus","year":"2012","unstructured":"Heiligenhaus A, Michels H, Schumacher C, Kopp I, Neudorf U, Niehues T, Baus H, Becker M, Bertram B, Dannecker G, et al. Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int. 2012;32(5):1121\u201333.","journal-title":"Rheumatol Int."},{"issue":"6","key":"1697_CR14","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1097\/SCS.0b013e3182646043","volume":"23","author":"JM Lee","year":"2012","unstructured":"Lee JM, Lee H, Park M, Baek S. Subconjunctival injection of triamcinolone for the treatment of upper lid retraction associated with thyroid eye disease. J Craniofac Surg. 2012;23(6):1755\u20138.","journal-title":"J Craniofac Surg."},{"issue":"7","key":"1697_CR15","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1442-9071.2010.02332.x","volume":"38","author":"AA Alkawas","year":"2010","unstructured":"Alkawas AA, Hussein AM, Shahien EA. Orbital steroid injection versus oral steroid therapy in management of thyroid-related ophthalmopathy. Clin Exp Ophthalmol. 2010;38(7):692\u20137.","journal-title":"Clin Exp Ophthalmol."},{"issue":"5","key":"1697_CR16","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1001\/archneur.57.5.750","volume":"57","author":"MA Agius","year":"2000","unstructured":"Agius MA. Treatment of ocular myasthenia with corticosteroids: yes. Arch Neurol. 2000;57(5):750\u20131.","journal-title":"Arch Neurol."},{"key":"1697_CR17","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1196\/annals.1405.037","volume":"1132","author":"J Soltys","year":"2008","unstructured":"Soltys J, Gong B, Kaminski HJ, Zhou Y, Kusner LL. Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment? Ann N Y Acad Sci. 2008;1132:220\u20134.","journal-title":"Ann N Y Acad Sci"},{"issue":"10","key":"1697_CR18","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1136\/bjo.2004.063404","volume":"89","author":"MJ Kupersmith","year":"2005","unstructured":"Kupersmith MJ, Ying G. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment. Br J Ophthalmol. 2005;89(10):1330\u20134.","journal-title":"Br J Ophthalmol."},{"issue":"3","key":"1697_CR19","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s00417-012-2227-x","volume":"251","author":"KA Park","year":"2013","unstructured":"Park KA, Oh SY. Treatment for diplopia in patients with myasthenia gravis. Graefes Arch Clin Exp Ophthalmol. 2013;251(3):895\u2013901.","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"issue":"2","key":"1697_CR20","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1212\/WNL.34.2.170","volume":"34","author":"A Sghirlanzoni","year":"1984","unstructured":"Sghirlanzoni A, Peluchetti D, Mantegazza R, Fiacchino F, Cornelio F. Myasthenia gravis: prolonged treatment with steroids. Neurology. 1984;34(2):170\u20134.","journal-title":"Neurology."},{"issue":"5","key":"1697_CR21","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/ana.410140504","volume":"14","author":"CJ Bever","year":"1983","unstructured":"Bever CJ, Aquino AV, Penn AS, Lovelace RE, Rowland LP. Prognosis of ocular myasthenia. Ann Neurol. 1983;14(5):516\u20139.","journal-title":"Ann Neurol."},{"issue":"5","key":"1697_CR22","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1136\/bjo.2009.172106","volume":"94","author":"K Nan","year":"2010","unstructured":"Nan K, Sun S, Li Y, Qu J, Li G, Luo L, Chen H, Cheng L. Characterisation of systemic and ocular drug level of triamcinolone acetonide following a single sub-Tenon injection. Br J Ophthalmol. 2010;94(5):654\u20138.","journal-title":"Br J Ophthalmol."},{"issue":"5","key":"1697_CR23","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00417-009-1269-1","volume":"248","author":"M Roesel","year":"2010","unstructured":"Roesel M, Heinz C, Koch JM, Heiligenhaus A. Comparison of orbital floor triamcinolone acetonide and oral prednisolone for cataract surgery management in patients with non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2010;248(5):715\u201320.","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"1697_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jns.2019.05.003","volume":"402","author":"Y Ozawa","year":"2019","unstructured":"Ozawa Y, Uzawa A, Kanai T, Oda F, Yasuda M, Kawaguchi N, Himuro K, Kuwabara S. Efficacy of high-dose intravenous methylprednisolone therapy for ocular myasthenia gravis. J Neurol Sci. 2019;402:12\u20135.","journal-title":"J Neurol Sci."},{"key":"1697_CR25","doi-asserted-by":"publisher","first-page":"116740","DOI":"10.1016\/j.jns.2020.116740","volume":"412","author":"T Sugimoto","year":"2020","unstructured":"Sugimoto T, Ochi K, Ishikawa R, Tazuma T, Hayashi M, Mine N, Naito H, Nomura E, Kohriyama T, Yamawaki T. Initial deterioration and intravenous methylprednisolone therapy in patients with myasthenia gravis. J Neurol Sci. 2020;412:116740.","journal-title":"J Neurol Sci."},{"issue":"2","key":"1697_CR26","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/jnnp.62.2.156","volume":"62","author":"N Sommer","year":"1997","unstructured":"Sommer N, Sigg B, Melms A, Weller M, Schepelmann K, Herzau V, Dichgans J. Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry. 1997;62(2):156\u201362.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"2","key":"1697_CR27","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1001\/archneur.60.2.243","volume":"60","author":"MJ Kupersmith","year":"2003","unstructured":"Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol. 2003;60(2):243\u20138.","journal-title":"Arch Neurol."},{"issue":"4","key":"1697_CR28","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/00041327-200312000-00002","volume":"23","author":"J Mee","year":"2003","unstructured":"Mee J, Paine M, Byrne E, King J, Reardon K, O'Day J. Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuroophthalmol. 2003;23(4):251\u20135.","journal-title":"J Neuroophthalmol."},{"issue":"2","key":"1697_CR29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jns.2003.08.017","volume":"217","author":"NT Monsul","year":"2004","unstructured":"Monsul NT, Patwa HS, Knorr AM, Lesser RL, Goldstein JM. The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci. 2004;217(2):131\u20133.","journal-title":"J Neurol Sci."}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01697-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12886-020-01697-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01697-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T01:33:30Z","timestamp":1603935210000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-020-01697-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,28]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1697"],"URL":"https:\/\/doi.org\/10.1186\/s12886-020-01697-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-25812\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-25812\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-25812\/v3","asserted-by":"object"}]},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,28]]},"assertion":[{"value":"4 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Wuhan Aier Eye Hospital(Hanyang), China (2016IRBKYA022). Written informed consent was obtained from each patient or their parents (for children <\u200918\u2009years of age) prior to participation in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We have obtained explicit written informed consent to publish all data (including individual details, images, and videos) related to the study from patients or their parents.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"432"}}